Effect of Fenofibrate Medication on Renal Function
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Fibrates are widely used to treat hypertriglyceridemia, a risk factor for arteriosclerosis, but these com-pounds have been associated with renal dysfunction. This study aimed to investigate the effects of fibrates on renal function in relatively healthy adult subjects with no cardiovascular diseases.Methods: This retrospective study included 558 outpatients who were prescribed 160 mg fenofibrate (fenofibrate group) or 10 mg atorvastatin (control group) between August 2007 and October 2015. The groups were randomly matched using propensity scores at a 1:1 ratio. Serum creatinine levels and estimated glomerular filtration rates be-fore and after treatment were compared between the two groups.Results: Patients in the fenofibrate group showed greater changes in serum creatinine levels than those in the con-trol group (9.73%±9.83% versus -0.89%±7.37%, P<0.001). Furthermore, 55.1% of patients in the fenofibrate group, but only 6.1% of those in the control group, exhibited a serum creatinine level increase ≥0.1 mg/dL (P<0.001). The fenofibrate group showed significantly greater declines in the estimated glomerular filtration rate than the control group (-10.1%±9.48% versus 1.42%±9.42%, P<0.001). Moreover, 34.7% of the fenofibrate group, but only 4.1% of the control group, exhibited an estimated glomerular filtration rate decrease ≥10 mL/min·1.73 m2 (P<0.001).Conclusion: Fenofibrate treatment resulted in increased serum creatinine levels and reduced estimated glomeru-lar filtration rates in a primary care setting. Therefore, regular renal function monitoring should be considered es-sential during fibrate administration.
Abstract
Background: Fibrates are widely used to treat hypertriglyceridemia, a risk factor for arteriosclerosis, but these com-pounds have been associated with renal dysfunction. This study aimed to investigate the effects of fibrates on renal function in relatively healthy adult subjects with no cardiovascular diseases.Methods: This retrospective study included 558 outpatients who were prescribed 160 mg fenofibrate (fenofibrate group) or 10 mg atorvastatin (control group) between August 2007 and October 2015. The groups were randomly matched using propensity scores at a 1:1 ratio. Serum creatinine levels and estimated glomerular filtration rates be-fore and after treatment were compared between the two groups.Results: Patients in the fenofibrate group showed greater changes in serum creatinine levels than those in the con-trol group (9.73%±9.83% versus -0.89%±7.37%, P<0.001). Furthermore, 55.1% of patients in the fenofibrate group, but only 6.1% of those in the control group, exhibited a serum creatinine level increase ≥0.1 mg/dL (P<0.001). The fenofibrate group showed significantly greater declines in the estimated glomerular filtration rate than the control group (-10.1%±9.48% versus 1.42%±9.42%, P<0.001). Moreover, 34.7% of the fenofibrate group, but only 4.1% of the control group, exhibited an estimated glomerular filtration rate decrease ≥10 mL/min·1.73 m2 (P<0.001).Conclusion: Fenofibrate treatment resulted in increased serum creatinine levels and reduced estimated glomeru-lar filtration rates in a primary care setting. Therefore, regular renal function monitoring should be considered es-sential during fibrate administration.
참고문헌 (35)
- Shah A, "The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans", Atherosclerosis, 210, pp.35~40 (2010)
- Baigent C, "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
- Cho JH, "Effect of fenofibrate therapy on blood creatinine levels in patients with hypertension and hypertriglyceridemia", J Lipid Atheroscler, 2, pp.19~26 (2013)
- Stone NJ, "ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25Pt B)[DOI]
- National Cholesterol Education Program Expert Panel on Detection, "Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- 고광곤, "Hypertriglyceridemia and Cardiovascular Diseases: Revisited", Korean Circulation Journal, 46(2), pp.135~144 (2016), 대한심장학회[DOI]
- Abourbih S, "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review", Am J Med, 122, pp.962.e1~962.e8 (2009)
- Davidson MH, "Safety considerations with fibrate therapy", Am J Cardiol, 99, pp.3C~18C (2007)
- Rossner S, "Fenofibrate therapy of hyperlipoproteinaemia : a dose-response study and a comparison with clofibrate", Atherosclerosis, 38, pp.273~282 (1981)
- Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus(the FIELD study) : randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
- ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
- Lageder H, "Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia", Wien Klin Wochenschr, 92, pp.95~101 (1980)
- Dick TB, "Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia", Curr Med Res Opin, 7, pp.489~502 (1981)
- Attridge RL, "Fenofibrate-associated nephrotoxicity : a review of current evidence", Am J Health Syst Pharm, 70, pp.1219~1225 (2013)
- Hukkanen J, "The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity", Br J Clin Pharmacol, 80, pp.473~479 (2015)
- Takazakura A, "Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy", J Diabetes Investig, 6, pp.346~353 (2015)
- 이창화, "임상에서 사용하는 사구체여과율의 평가 공식", 대한내과학회지, 83(4), pp.455~457 (2012), 대한내과학회[DOI]
- Austin PC, "Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies", Pharm Stat, 10, pp.150~161 (2011)
- Backes JM, "Fibrates : what have we learned in the past 40 years?", Pharmacotherapy, 27, pp.412~424 (2007)
- Jacobson TA, "Hypertriglyceridemia and cardiovascular risk reduction", Clin Ther, 29, pp.763~777 (2007)
- Yuan G, "Hypertriglyceridemia: its etiology, effects and treatment", CMAJ, 176, pp.1113~1120 (2007)
- Angeles C, "Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients : biopsy evidence of tubular toxicity", Am J Kidney Dis, 44, pp.543~550 (2004)
- Keating GM, "Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus", Drugs, 67, pp.121~153 (2007)
- Remick J, "Fibrate therapy : an update", Cardiol Rev, 16, pp.129~141 (2008)
- Broeders N, "Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?", Nephrol Dial Transplant, 15, pp.1993~1999 (2000)
- Paul S, "Fenofibrate can increase serum creatinine levels in renal insufficiency", J Assoc Physicians India, 54, pp.337~ (2006)
- McQuade CR, "Elevated serum creatinine levels associated with fenofibrate therapy", Am J Health Syst Pharm, 65, pp.138~141 (2008)
- Lipscombe J, "Deterioration in renal function associated with fibrate therapy", Clin Nephrol, 55, pp.39~44 (2001)
- Ritter JL, "Fenofibrate-induced elevation in serum creatinine", Pharmacotherapy, 21, pp.1145~1149 (2001)
- Ansquer JC, "Effect of fenofibrate on kidney function : a 6-week randomized crossover trial in healthy people", Am J Kidney Dis, 51, pp.904~913 (2008)
- Hottelart C, "Fenofibrate increases creatininemia by increasing metabolic production of creatinine", Nephron, 92, pp.536~541 (2002)
- Attridge RL, "Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity", J Clin Lipidol, 6, pp.19~26 (2012)
- Forsblom C, "Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes : the FIELD Helsinki substudy", Diabetes Care, 33, pp.215~220 (2010)
- Mychaleckyj JC, "Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants", Diabetes Care, 35, pp.1008~1014 (2012)
- Patel P, "Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: a randomized, open-label, multicenter clinical trial in Indian population", Indian J Endocrinol Metab, 20, pp.67~71 (2016)